VERISILICON
14.3.2024 01:01:27 CET | Business Wire | Press release
VeriSilicon (688521.SH) today announced the integration of its Image Signal Processor (ISP) IP ISP8000, DeWarp Processor IP DW200, and 2.5D Graphics Processor Unit (GPU) IP GCNanoV into Canaan’s K230 chip, the world’s first commercial mass production edge AIoT chip supporting the RISC-V Vector 1.0 standard. This collaboration marks a significant advancement in the high-precision, low-latency edge AIoT solutions for a wide range of intelligent products, such as large-model and multimodal input edge terminals, 3D-structured light perception modules, interactive robots, open-source hardwares, as well as hardwares for smart manufacturing, smart home solutions and AI education.
VeriSilicon’s ISP8000 IP is capable of real-time processing of three or more streams of high-definition video. Its 20-bit depth pipeline architecture supports advanced image processing algorithms such as triple-exposure High Dynamic Range (HDR) and 3D Noise Reduction (3DNR). ISP8000’s optimized software collaborates seamlessly with the RISC-V processors to efficiently manage and schedule system resources. On the K230 chip, leveraging the RT-Thread real-time operating system and the performance and power advantages of the RISC-V processors, ISP8000 can perform real-time scheduling and efficiently run software under a dual-core processor architecture. It is perfectly compatible with the K230 Software Development Kit (SDK), supporting RTOS and Linux dual operating systems, achieving an optimal balance between real-time and non-real-time operations.
VeriSilicon’s DW200 IP not only precisely corrects distortions in wide-angle or fisheye lens, but also supports multi-channel downscaling output through low-bandwidth direct link mode, enriching user application scenarios, and is particularly suited for AI applications with diverse spatial output requirements. For MCU/MPU devices, VeriSilicon’s low-power 2.5D GPU IP delivers high-performance and high-quality vector graphics processing capabilities along with superior image output.
Hong-Gang Wang, VP of research and development at Canaan said, “Leveraging VeriSilicon’s advanced pixel processing IP portfolio, our RISC-V based K230 achieved leading performance and image quality compared with other edge AIoT SoCs in its class. This enables more edge device vendors to develop innovative products with broader market applications. VeriSilicon’s ISP is one of the key factors driving innovation in our edge AIoT SoCs.”
“RISC-V is increasingly important in embedded products. We have partnered with all leading RISC-V CPU IP vendors to ensure our comprehensive Glass-to-Glass (from camera-in to display-out) intelligent pixel processing IP portfolio collaborates seamlessly and efficiently with RISC-V architectures,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “Through our close collaboration with Canaan, the edge AIoT SoC K230 has achieved high image quality while maintaining low power consumption and latency. Moreover, K230 can support multiple sensors leveraging the advanced Multi-Context Management (MCM) feature of ISP8000, further enhancing its market competitiveness.”
About Canaan Inc.
Canaan Inc. (Nasdaq: CAN) is a leading provider of high-performance ASIC chips. With a diversified strategy centered on “blockchain + AI”, Canaan is dedicated to the research and development of high-performance ASIC computing chips, AI chips, and devices. As a Nasdaq-listed company, Canaan holds the distinction of being the world’s “first blockchain stock company” and the initial Chinese firm with independent intellectual property in AI chips to be listed in the US. Canaan is committed to harnessing ASIC technology to achieve its mission of “Super Computing Is What We Do, Social Enrichment is Why We Do”, positioning itself as a leader in high-performance computing for blockchain and AI.
For more information, please visit: canaan.io
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313405660/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom